Oncternal Therapeutics Inc(NASDAQ:ONCT) stock News

ONCT Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Oncternal Therapeutics

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

7 months ago - By: Oncternal Therapeutics

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

11 months ago - By: Benzinga - Mentions: SCNI EYEN SRRK XCUR ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

11 months ago - By: Benzinga - Mentions: QUBT SAVA BBIO CMAX ...

Gold Down Over 3%; Rigetti Computing Shares Spike Higher

a year ago - By: BusinessInsider

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

a year ago - By: BusinessInsider

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

a year ago - By: InvestorPlace

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

a year ago - By: Oncternal Therapeutics

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

a year ago - By: InvestorPlace

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

a year ago - By: Oncternal Therapeutics

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

1 years ago - By: Oncternal Therapeutics

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

2 years ago - By: Oncternal Therapeutics

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

2 years ago - By: BusinessInsider

ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

2 years ago - By: InvestorPlace

ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

2 years ago - By: Oncternal Therapeutics

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

2 years ago - By: Oncternal Therapeutics

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

2 years ago - By: Oncternal Therapeutics

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

2 years ago - By: Oncternal Therapeutics

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

2 years ago - By: Seeking Alpha

Oncternal Therapeutics announces a reverse stock split (NASDAQ:ONCT)

2 years ago - By: Oncternal Therapeutics

Oncternal Therapeutics Inc (ONCT) Stock News

ONCT Latest News, Press Relases and Analysis

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gold Down Over 3%; Rigetti Computing Shares Spike Higher

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics announces a reverse stock split (NASDAQ:ONCT)

Oncternal Therapeutics Announces Reverse Stock Split